Research synthesis only; not medical advice. Sterility assurance, pyrogen control, and aseptic technique are complex pharmaceutical disciplines. This page explains the foundational principles; it does not provide instructions for the preparation or handling of any specific product.
Sterility assurance
Sterility is defined as the absence of viable microorganisms. In pharmaceutical practice, sterility cannot be proven absolutely for any batch; instead, it is expressed as the sterility assurance level (SAL) — the probability that a single unit in a batch is non-sterile. The compendial standard for parenteral products is SAL ≤ 10⁻⁶ (1 in 1,000,000).
Terminal sterilization vs. aseptic processing
| Method | Principle | When applicable | SAL achievable |
|---|---|---|---|
| Terminal sterilization (moist heat) | Product filled and sealed, then sterilized in final container by autoclaving (121°C, 15 min) | Product must withstand high temperature; preferred by regulators whenever feasible | 10⁻⁶ or better |
| Terminal sterilization (ionizing radiation or ethylene oxide) | Radiation (gamma, e-beam) or gas kills microorganisms | For heat-sensitive products compatible with radiation/EtO; less common for peptides due to oxidation risk | 10⁻⁶ achievable with validated dose |
| Aseptic processing | Each component (drug solution, container, closure) sterilized separately, then filled in a controlled environment | Required when the product cannot be terminally sterilized | No validated SAL; sterility assurance depends on environmental monitoring, media fills, and process controls |
Most peptide products are manufactured by aseptic processing because the peptide would degrade under terminal sterilization conditions.
Aseptic processing controls
Aseptic filling requires:
Grade A (ISO 5) environment: Unidirectional airflow (HEPA-filtered, ≥0.45 m/s), ≤3,520 particles ≥0.5 µm/m³ at rest
Grade B background: Surrounding cleanroom (ISO 7) for access and support
Personnel barriers: Full sterile gowning, gloves, masks; restricted access
Media fills: Process simulation using sterile nutrient medium to demonstrate aseptic technique; typically 3 successful fills of 5,000--10,000 units per shift per site
Viable monitoring: Active air sampling, settle plates, contact plates for surfaces, finger dabs
FDA guidance requires that "any operation that exposes a sterile drug product to the environment must be performed in an aseptic processing suite" (FDA 2004 Aseptic Processing Guidance).
Endotoxin and pyrogen control
Endotoxin (lipopolysaccharide, LPS) is a component of the outer membrane of Gram-negative bacteria that is shed during cell growth and lysis. When introduced into the bloodstream or cerebrospinal fluid, endotoxin triggers a potent inflammatory response via Toll-like receptor 4 (TLR4), producing fever, hypotension, shock, and potentially death.
Limits (USP <85>, Ph. Eur. 2.6.14):
| Route | Endotoxin limit |
|---|---|
| Intrathecal | ≤0.2 EU/kg/hour |
| Intravenous (general) | ≤5.0 EU/kg/hour |
| Intravenous (radiolabelled products) | ≤2.5 EU/kg/hour |
EU = endotoxin units, measured by Limulus amebocyte lysate (LAL) or recombinant Factor C (rFC) assay.
Pyrogen testing (USP <151>) also detects non-endotoxin pyrogens (e.g., bacterial peptidoglycans, fungal beta-glucans). Rabbit pyrogen testing is increasingly replaced by the monocyte activation test (MAT) per Ph. Eur. 2.6.30 and FDA guidance.
Bioburden control
Before sterilization, the bioburden (total microbial load) of process streams is controlled: typical limits are ≤10 CFU/100 mL for water for injection and ≤100 CFU/g for active pharmaceutical ingredient. Excessive bioburden can generate endotoxin even if the final sterilization kills the organisms.
Container-closure integrity
The container-closure system must maintain sterility throughout the product's shelf life. Integrity testing methods include:
Deterministic methods: Helium leak detection, vacuum decay, pressure decay
Probabilistic methods: Dye ingress (methylene blue immersion), microbial immersion
FDA guidance (2008) recommends deterministic methods for stability protocols. Container-closure integrity must be demonstrated over the full shelf life, accounting for stopper relaxation, seal degradation, and temperature cycling.
Multi-dose vial risks
Multi-dose vials contain an antimicrobial preservative (e.g., benzyl alcohol 0.9%, phenol 0.25%, m-cresol 0.3%) and are labeled for use within a specified period after first puncture (typically 28 days). Risks include:
Preservative efficacy depends on concentration and must be demonstrated per USP
<51>(antimicrobial effectiveness test)Preservative can cause allergic or toxic reactions (benzyl alcohol is contraindicated in neonates — "gasping syndrome")
Improper storage after first use (refrigeration required if labeled)
Contamination during repeated needle entry despite preservative
Sources
FDA. Guidance for Industry: Sterile Drug Products Produced by Aseptic Processing — Current Good Manufacturing Practice. 2004. https://www.fda.gov/media/71026/download
USP General Chapter
<85>Bacterial Endotoxins Test. USP–NF. Rockville, MD: United States Pharmacopeia; 2026.USP General Chapter
<151>Pyrogen Test. USP–NF. Rockville, MD: United States Pharmacopeia; 2026.USP General Chapter
<51>Antimicrobial Effectiveness Test. USP–NF. Rockville, MD: United States Pharmacopeia; 2026.USP General Chapter
<1151>Pharmaceutical Dosage Forms. USP–NF. Rockville, MD: United States Pharmacopeia; 2026.FDA. Guidance for Industry: Container and Closure System Integrity Testing in Lieu of Sterility Testing as a Component of the Stability Protocol for Sterile Products. 2008.
World Health Organization. WHO Good Manufacturing Practices for Sterile Pharmaceutical Products. WHO Technical Report Series, No. 1025, Annex 3. 2020.
Ph. Eur. 2.6.14 Bacterial Endotoxins. European Pharmacopoeia 11th ed. Strasbourg: EDQM; 2026.
Ph. Eur. 2.6.30 Monocyte-activation test. European Pharmacopoeia 11th ed. Strasbourg: EDQM; 2026.